Clinical Topics   /   Oncology

Therapy Combinations Were Safe, Active in Genitourinary Cancer Trials

by Annette Boyle
June 1, 2018

BETHESDA, MD — Federal researchers reported updated results of trials of cabozantinib plus nivolumab with and without ipilimumab in patients with refractory metastatic urothelial carcinoma on Saturday at the 2018 American Society of Clinical Oncology Annual Meeting. The new data shows improving trends for duration of response and progression free survival.

Rosa Maria Nadal, MD, of the National Cancer Institute, presented the results of the phase 1 dose and expansion cohorts study, which enrolled 30 patients with metastatic urothelial carcinoma refractory to chemotherapy. The researchers assigned 15 patients who had never received checkpoint inhibitors to receive CaboNivo and eight to receive CaboNivoIpi. Seven patients who had relapsed on checkpoint inhibitors received CaboNivo. Patients remained on therapy until progression or unacceptable toxicity was reached.

The interim report presented outcomes after 11.9 months of follow up for the total cohort. Among checkpoint inhibitor naive patients, the objective response rate for CaboNivo reached 50%. Median duration of response was 24.1 months and median progression free survival was 24.1 months, though in both cases, the upper end of the range had not been reached. Overall survival was not yet reportable.

Checkpoint inhibitor naive patients who received CaboNivoIpi had an objective response rate of 33% and median progression free survival of 10.1, with the upper limit still not reached. Neither duration of response nor overall survival had matured sufficiently to report.

Common grade 3 or higher adverse effects included fatigue (17%), hypertension (14%), thromboembolic events (14%) lipase elevation (31%), hypophatemia (17%), hyponatremia (10%). Four patients had grade 3 or higher immune-related adverse effects including meningitis, pneumonitis and colitis.

Nadal presented earlier results at the 2018 American Society of Clinical Oncology Genitourinary Cancers Symposium that demonstrated that cabozantinib combined with nivolumab with or without ipilimumab increased antitumor activity in patients with relapsed metastatic RCC and other advanced genitourinary tumors.2

In patients with metastatic urothelial carcinoma, the cabozantinib/nivolumab combination achieved an objective response rate of 50%, while cabozantinib/nivolumab/ipilimumab had a 29% response rate at data closure for the earlier report. Median progression free survival was 12.8 months for both regimens and median overall survival had not been reached at that time.


1Nadal RM, Martazavi A, Stein MN. Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients with chemotherapy-refractory metastatic urothelial carcinoma either naive or refractory to checkpoint inhibitors. Clin Oncol 36, 2018 (suppl; abstr 4528).

2Nadal RM, Mortazavi A, Stein M, et al. Results of phase I plus expansion cohorts of cabozantinib plus nivolumab and CaboNivo plus ipilimumab in patients with metastatic urothelial carcinoma and other genitourinary malignancies. J Clin Oncol 36, February 20, 2018 (no. 6 suppl; abstr 515).

Related Articles

New Agents Extend Options for Increased Survival in Metastatic Prostate Cancer

Accounting for nearly a third of all cancer diagnoses, prostate cancer is the most frequently diagnosed cancer in the VHA, where past research has suggested that the malignancy is caught earlier than in other healthcare systems.

Personalized Medicine Brightens Outlook for Most Common Kidney Cancer

In the past five years, 10 new system therapies have been approved for renal cell carcinoma (RCC), the most common type of kidney cancer.


U.S. Medicine Recommends


More From oncology

Oncology

New Agents Extend Options for Increased Survival in Metastatic Prostate Cancer

Accounting for nearly a third of all cancer diagnoses, prostate cancer is the most frequently diagnosed cancer in the VHA, where past research has suggested that the malignancy is caught earlier than in other healthcare systems.

Oncology

Personalized Medicine Brightens Outlook for Most Common Kidney Cancer

In the past five years, 10 new system therapies have been approved for renal cell carcinoma (RCC), the most common type of kidney cancer.

Oncology

Targeted Therapies Transform RCC Treatment Over Last Decade

In the last decade, the development of multiple molecular-targeted therapies has dramatically altered the treatment landscape for advanced renal cell carcinoma (RCC).

Oncology

Liver Cancer Continues to Rise, Even as VA Declares Victory Over HCV Infection

In March, then-VA Secretary David Shulkin, MD, announced at the annual Wharton Health Care Business Conference that the VA will have eliminated hepatitis C infections among all patients willing and able to be treated by next spring.

Oncology

Undertreatment of Metastatic Pancreatic Cancer Treatment, Despite Guidelines

While many other cancers have seen dramatic improvement in outcomes in the past 20 years, pancreatic cancer remains one of the deadliest malignancies, regardless of stage at diagnosis, with an overall five-year survival rate of only 8%, according to the American Cancer Society.

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up